The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-β-carbomethoxy-3-β-(4-fluorophenyl)-tropane in patients with movement disorders

Giovanni Lucignani, C. Gobbo, R. M. Moresco, A. Antonini, A. Panzacchi, L. Bonaldi, A. Carpinelli, T. Caraceni, F. Fazio

Research output: Contribution to journalArticle

Abstract

Movement disorders, including Parkinson's disease and parkinsonian syndromes, e.g. progressive supranuclear palsy, multiple system atrophy, and Lewy body dementia, may be difficult to differentiate among each other at an early stage, since they may share similar clinical features and response to dopaminergic drugs. As new tracers for imaging the dopamine transporters become available, the use of positron emission tomography (PET) for the differential diagnosis of movement disorders is gaining clinical relevance. Visual interpretation is generally used for PET image analysis. However, the use of some form of less subjective analysis is desirable in order to detect subtle changes that may be difficult to identify by visual interpretation and to achieve an operator independent analysis. To this end this study was aimed at assessing the feasibility of using statistical parametric mapping (SPM) for the clinical evaluation of single PET scans performed with 2-β-carbomethoxy-3-β-(4-fluorophenyl)-tropane (11C-β-CIT-FE). Eleven healthy volunteers and five patients with movement disorders (Parkinson's disease, essential tremor, PSP and Lewy body dementia) were included in this study. Each subject underwent a PET study after i.v. injection of 11C-β-CIT-FE. The PET images of 11C-β-CIT-FE distribution acquired between 60 and 90 min were spatially fitted into the Talairach and Tournoux space. A template of normal 11C-β-CIT-FE distribution was derived from studies in the 11 normal control subjects. Different patterns of reduction of the uptake of the tracer were detected in the basal ganglia of the five patients, in relation to each pathological condition. The patterns of distribution were all consistent with the severity and type of disease. The results of this study demonstrate the feasibility of differentiating among different states of dopaminergic impairment, due to Parkinson's disease and parkinsonian syndromes, by using PET scans with 11C-β-CIT-FE and by using the SPM procedure for analysis of the data. (

Original languageEnglish
Pages (from-to)1047-1055
Number of pages9
JournalNuclear Medicine Communications
Volume23
Issue number11
DOIs
Publication statusPublished - Nov 1 2002

Fingerprint

Movement Disorders
Positron-Emission Tomography
Parkinson Disease
Lewy Body Disease
Parkinsonian Disorders
Essential Tremor
Progressive Supranuclear Palsy
Multiple System Atrophy
Dopamine Agents
Dopamine Plasma Membrane Transport Proteins
Feasibility Studies
Basal Ganglia
methyl ester (1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid
Healthy Volunteers
Differential Diagnosis
Injections

Keywords

  • Dopamine transporter
  • Movement disorders
  • Statistical parametric mapping

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-β-carbomethoxy-3-β-(4-fluorophenyl)-tropane in patients with movement disorders. / Lucignani, Giovanni; Gobbo, C.; Moresco, R. M.; Antonini, A.; Panzacchi, A.; Bonaldi, L.; Carpinelli, A.; Caraceni, T.; Fazio, F.

In: Nuclear Medicine Communications, Vol. 23, No. 11, 01.11.2002, p. 1047-1055.

Research output: Contribution to journalArticle

Lucignani, Giovanni ; Gobbo, C. ; Moresco, R. M. ; Antonini, A. ; Panzacchi, A. ; Bonaldi, L. ; Carpinelli, A. ; Caraceni, T. ; Fazio, F. / The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-β-carbomethoxy-3-β-(4-fluorophenyl)-tropane in patients with movement disorders. In: Nuclear Medicine Communications. 2002 ; Vol. 23, No. 11. pp. 1047-1055.
@article{412c9d4991074e7d8a5cd013102d28eb,
title = "The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-β-carbomethoxy-3-β-(4-fluorophenyl)-tropane in patients with movement disorders",
abstract = "Movement disorders, including Parkinson's disease and parkinsonian syndromes, e.g. progressive supranuclear palsy, multiple system atrophy, and Lewy body dementia, may be difficult to differentiate among each other at an early stage, since they may share similar clinical features and response to dopaminergic drugs. As new tracers for imaging the dopamine transporters become available, the use of positron emission tomography (PET) for the differential diagnosis of movement disorders is gaining clinical relevance. Visual interpretation is generally used for PET image analysis. However, the use of some form of less subjective analysis is desirable in order to detect subtle changes that may be difficult to identify by visual interpretation and to achieve an operator independent analysis. To this end this study was aimed at assessing the feasibility of using statistical parametric mapping (SPM) for the clinical evaluation of single PET scans performed with 2-β-carbomethoxy-3-β-(4-fluorophenyl)-tropane (11C-β-CIT-FE). Eleven healthy volunteers and five patients with movement disorders (Parkinson's disease, essential tremor, PSP and Lewy body dementia) were included in this study. Each subject underwent a PET study after i.v. injection of 11C-β-CIT-FE. The PET images of 11C-β-CIT-FE distribution acquired between 60 and 90 min were spatially fitted into the Talairach and Tournoux space. A template of normal 11C-β-CIT-FE distribution was derived from studies in the 11 normal control subjects. Different patterns of reduction of the uptake of the tracer were detected in the basal ganglia of the five patients, in relation to each pathological condition. The patterns of distribution were all consistent with the severity and type of disease. The results of this study demonstrate the feasibility of differentiating among different states of dopaminergic impairment, due to Parkinson's disease and parkinsonian syndromes, by using PET scans with 11C-β-CIT-FE and by using the SPM procedure for analysis of the data. (",
keywords = "Dopamine transporter, Movement disorders, Statistical parametric mapping",
author = "Giovanni Lucignani and C. Gobbo and Moresco, {R. M.} and A. Antonini and A. Panzacchi and L. Bonaldi and A. Carpinelli and T. Caraceni and F. Fazio",
year = "2002",
month = "11",
day = "1",
doi = "10.1097/00006231-200211000-00003",
language = "English",
volume = "23",
pages = "1047--1055",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-β-carbomethoxy-3-β-(4-fluorophenyl)-tropane in patients with movement disorders

AU - Lucignani, Giovanni

AU - Gobbo, C.

AU - Moresco, R. M.

AU - Antonini, A.

AU - Panzacchi, A.

AU - Bonaldi, L.

AU - Carpinelli, A.

AU - Caraceni, T.

AU - Fazio, F.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Movement disorders, including Parkinson's disease and parkinsonian syndromes, e.g. progressive supranuclear palsy, multiple system atrophy, and Lewy body dementia, may be difficult to differentiate among each other at an early stage, since they may share similar clinical features and response to dopaminergic drugs. As new tracers for imaging the dopamine transporters become available, the use of positron emission tomography (PET) for the differential diagnosis of movement disorders is gaining clinical relevance. Visual interpretation is generally used for PET image analysis. However, the use of some form of less subjective analysis is desirable in order to detect subtle changes that may be difficult to identify by visual interpretation and to achieve an operator independent analysis. To this end this study was aimed at assessing the feasibility of using statistical parametric mapping (SPM) for the clinical evaluation of single PET scans performed with 2-β-carbomethoxy-3-β-(4-fluorophenyl)-tropane (11C-β-CIT-FE). Eleven healthy volunteers and five patients with movement disorders (Parkinson's disease, essential tremor, PSP and Lewy body dementia) were included in this study. Each subject underwent a PET study after i.v. injection of 11C-β-CIT-FE. The PET images of 11C-β-CIT-FE distribution acquired between 60 and 90 min were spatially fitted into the Talairach and Tournoux space. A template of normal 11C-β-CIT-FE distribution was derived from studies in the 11 normal control subjects. Different patterns of reduction of the uptake of the tracer were detected in the basal ganglia of the five patients, in relation to each pathological condition. The patterns of distribution were all consistent with the severity and type of disease. The results of this study demonstrate the feasibility of differentiating among different states of dopaminergic impairment, due to Parkinson's disease and parkinsonian syndromes, by using PET scans with 11C-β-CIT-FE and by using the SPM procedure for analysis of the data. (

AB - Movement disorders, including Parkinson's disease and parkinsonian syndromes, e.g. progressive supranuclear palsy, multiple system atrophy, and Lewy body dementia, may be difficult to differentiate among each other at an early stage, since they may share similar clinical features and response to dopaminergic drugs. As new tracers for imaging the dopamine transporters become available, the use of positron emission tomography (PET) for the differential diagnosis of movement disorders is gaining clinical relevance. Visual interpretation is generally used for PET image analysis. However, the use of some form of less subjective analysis is desirable in order to detect subtle changes that may be difficult to identify by visual interpretation and to achieve an operator independent analysis. To this end this study was aimed at assessing the feasibility of using statistical parametric mapping (SPM) for the clinical evaluation of single PET scans performed with 2-β-carbomethoxy-3-β-(4-fluorophenyl)-tropane (11C-β-CIT-FE). Eleven healthy volunteers and five patients with movement disorders (Parkinson's disease, essential tremor, PSP and Lewy body dementia) were included in this study. Each subject underwent a PET study after i.v. injection of 11C-β-CIT-FE. The PET images of 11C-β-CIT-FE distribution acquired between 60 and 90 min were spatially fitted into the Talairach and Tournoux space. A template of normal 11C-β-CIT-FE distribution was derived from studies in the 11 normal control subjects. Different patterns of reduction of the uptake of the tracer were detected in the basal ganglia of the five patients, in relation to each pathological condition. The patterns of distribution were all consistent with the severity and type of disease. The results of this study demonstrate the feasibility of differentiating among different states of dopaminergic impairment, due to Parkinson's disease and parkinsonian syndromes, by using PET scans with 11C-β-CIT-FE and by using the SPM procedure for analysis of the data. (

KW - Dopamine transporter

KW - Movement disorders

KW - Statistical parametric mapping

UR - http://www.scopus.com/inward/record.url?scp=0036854466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036854466&partnerID=8YFLogxK

U2 - 10.1097/00006231-200211000-00003

DO - 10.1097/00006231-200211000-00003

M3 - Article

C2 - 12411832

AN - SCOPUS:0036854466

VL - 23

SP - 1047

EP - 1055

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 11

ER -